Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company utilizes a proprietary tri-complex technology platform to discover and develop small molecules that inhibit the active, GTP-bound form of RAS proteins. Its core value proposition lies in addressing elusive frontier cancer targets through sophisticated structure-based drug discovery and precision medicine approaches.
Financials
Based on Q1 2026 filing
Revenue
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
RAS(ON) Inhibitors
primaryThe company's primary focus is a portfolio of compounds designed to bind directly to the active state of RAS variants. These inhibitors are being developed as monotherapies and in combination regimens to treat various solid tumors including pancreatic, lung, and colorectal cancers.
daraxonrasib (RMC-6236), zoldonrasib (RMC-9805), elironrasib (RMC-6291), RMC-5127, RMC-0708, RMC-8839
Patients with RAS-mutant cancers, Healthcare providers, Clinical trial sites
Segment Financials
Redwood City California — Payments For Proceeds From Tenant Allowance
View metricBusiness Overview
Competitive Position
A pioneer in RAS(ON) inhibition using a proprietary tri-complex platform to target the active form of RAS, differentiating itself from first-generation KRAS(OFF) inhibitors.
Geographies
United States, Europe, Asia
Customer Segments
Oncology patients, Hospitals, Specialty pharmacies
Upstream Dependencies
Contract Development and Manufacturing Organizations (CDMOs), Specialized chemical suppliers, Clinical research organizations
Downstream Customers
Hospitals and cancer centers, Specialty drug distributors, Government and private health insurers
Competitors & Partners
Competitors
Amgen
AMGN
Developer of KRAS(OFF) G12C inhibitor sotorasib
Eli Lilly
LLY
Developing KRAS G12C and G12D programs
BridgeBio Pharma
BBIO
Developing dual KRAS G12C (ON/OFF) programs
Bristol-Myers Squibb
BMY
Developer of KRAS(OFF) G12C inhibitor adagrasib
Pfizer
PFE
Developing mutant RAS programs
Merck & Co.
MRK
Developing KRAS G12C programs
Similar Companies
Partners
Bristol-Myers Squibb
BMY
Clinical collaboration to evaluate navlimetostat in combination with daraxonrasib
Amgen
AMGN
Clinical collaboration evaluating AMG 193 in combination with daraxonrasib
Summit Therapeutics
SMMT
Clinical collaboration evaluating RAS(ON) inhibitors with ivonescimab
Iambic Therapeutics
AI-driven lead discovery and optimization collaboration
Tango Therapeutics
TNGX
Clinical collaboration evaluating vopimetostat in combination with RAS(ON) inhibitors
Aethon Therapeutics, Inc.
Research collaboration for novel bispecific antibodies
Break Through Cancer
Biomarker identification research collaboration
Subsidiaries
EQRx, Inc.
Wholly-owned subsidiary acquired in November 2023
Revolution Medicines, Inc. FAQ
Common questions about Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company utilizes a proprietary tri-complex technology platform to discover and develop small molecules that inhibit the active, GTP-bound form of RAS proteins. Its core value proposition lies in addressing elusive frontier cancer targets through sophisticated structure-based drug discovery and precision medicine approaches.
Revolution Medicines, Inc. (RVMD) has a market capitalization of $32.2B and trades on NASDAQ.
Revolution Medicines, Inc.'s key competitors include Amgen Inc., Eli Lilly, BridgeBio Pharma, Inc., and others. These companies compete in similar markets and product categories.
Revolution Medicines, Inc. has approximately 411 employees.